Disc Medicine (NASDAQ:IRON) Upgraded to Strong-Buy at Raymond James

Disc Medicine (NASDAQ:IRON - Get Free Report) was upgraded by Raymond James from an "outperform" rating to a "strong-buy" rating in a research report issued to clients and investors on Monday, Marketbeat reports. The brokerage presently has a $110.00 price target on the stock, up from their prior price target of $66.00. Raymond James' target price suggests a potential upside of 88.84% from the stock's previous close.

Other equities research analysts have also issued research reports about the company. Scotiabank started coverage on Disc Medicine in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $62.00 price objective for the company. Wedbush restated an "outperform" rating and issued a $57.00 target price on shares of Disc Medicine in a research report on Friday, August 9th. Cantor Fitzgerald reissued an "overweight" rating and issued a $85.00 target price on shares of Disc Medicine in a research note on Tuesday, October 15th. HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of Disc Medicine in a report on Monday, October 28th. Finally, Wells Fargo & Company began coverage on Disc Medicine in a research note on Thursday, August 22nd. They issued an "overweight" rating and a $75.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $73.10.

Disc Medicine Trading Up 23.6 %

Shares of IRON stock traded up $11.12 during trading on Monday, hitting $58.25. The company's stock had a trading volume of 2,085,356 shares, compared to its average volume of 352,495. The business has a fifty day moving average of $48.58 and a 200-day moving average of $42.74. The company has a market cap of $1.73 billion, a PE ratio of -15.87 and a beta of 0.61. Disc Medicine has a 52 week low of $25.60 and a 52 week high of $77.60.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.11) by $0.08. As a group, research analysts predict that Disc Medicine will post -4.09 EPS for the current year.

Hedge Funds Weigh In On Disc Medicine

A number of institutional investors have recently bought and sold shares of IRON. Amalgamated Bank increased its position in Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company's stock worth $26,000 after buying an additional 247 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company's stock worth $54,000 after acquiring an additional 337 shares in the last quarter. SG Americas Securities LLC raised its stake in Disc Medicine by 19.5% during the 3rd quarter. SG Americas Securities LLC now owns 4,864 shares of the company's stock worth $239,000 after acquiring an additional 793 shares during the period. Bleakley Financial Group LLC lifted its holdings in Disc Medicine by 23.0% during the first quarter. Bleakley Financial Group LLC now owns 4,572 shares of the company's stock valued at $285,000 after purchasing an additional 856 shares in the last quarter. Finally, TD Asset Management Inc boosted its position in shares of Disc Medicine by 3.7% in the second quarter. TD Asset Management Inc now owns 40,732 shares of the company's stock worth $1,836,000 after purchasing an additional 1,468 shares during the period. 83.70% of the stock is owned by institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.